Healthcare Sector
Market Tracker
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Name | Pct Held | Shares | Total |
---|---|---|---|
Vanguard Extended Market Index Fund | 0.99% | 87.14k | 418.26k |
Vanguard Total Stock Market Index Fund | 0.86% | 75.95k | 364.56k |
Fidelity Extended Market Index Fund | 0.43% | 37.57k | 180.33k |
iShares Core S&P Total U.S. Stock Market ETF | 0.12% | 10.6k | 50.87k |
Fidelity Total Market Index Fund | 0.10% | 8.95k | 42.96k |
Vanguard Institutional Index-Inst Total Stock Market Ind | 0.06% | 5.69k | 27.31k |
Fidelity Series Total Market Index Fund | 0.06% | 5.6k | 26.9k |
Vanguard Balanced Index Fund | 0.06% | 5.5k | 26.38k |
Fidelity NASDAQ Composite Index Fund | 0.03% | 2.34k | 11.24k |
USAA Mutual Fd Tr-Extended Market Index Fd | 0.01% | 645 | 3.1k |
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
11/26 12:00 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
05/15 04:15 pm
GlobeNewswire Inc.
Read morePrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
04/08 07:00 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports Year-End 2023 Corporate and Financial Results
03/25 05:45 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
03/22 12:30 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
01/22 08:30 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
01/08 09:24 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
12/21 12:00 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/09 06:00 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
09/11 07:00 am
GlobeNewswire Inc.
Read moreMarker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08/30 08:00 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
08/14 04:30 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
08/07 07:00 am
GlobeNewswire Inc.
Read moreEuropean Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
07/10 07:00 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
06/26 07:00 am
GlobeNewswire Inc.
Read moreNasdaq Gains 1%; US Budget Deficit Widens In May
06/12 02:54 pm
Benzinga
Read moreMarker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
06/12 07:00 am
GlobeNewswire Inc.
Read moreUtilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
06/01 06:00 am
PennyStocks
Read moreNasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views
05/31 12:06 pm
Benzinga
Read moreMarker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
05/31 06:30 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
05/08 07:30 am
GlobeNewswire Inc.
Read more7 Low Float Penny Stocks To Watch After SNTG Stock Explodes
05/01 12:10 pm
PennyStocks
Read moreMarker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™
05/01 07:30 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
03/22 08:10 am
GlobeNewswire Inc.
Read moreMarker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
12/13 08:00 am
GlobeNewswire Inc.
Read moreMARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
11/10 06:35 pm
Zacks Investment Research
Read more3 Hot Penny Stocks To Buy For Under $1 Right Now
10/14 12:53 pm
PennyStocks
Read moreMarker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
09/13 07:00 am
GlobeNewswire Inc.
Read moreWhy ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
09/09 04:13 am
Benzinga
Read moreMarker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference
09/08 07:00 am
GlobeNewswire Inc.
Read moreWhy AMC Entertainment Is Trading Lower By 33%; Here Are 31 Stocks Moving Premarket
08/22 07:13 am
Benzinga
Read moreMarker Therapeutics Reports Q2 2022 Operating and Financial Results
08/11 04:22 pm
GlobeNewswire Inc.
Read more